The Resistant Hypertension drugs in development market research report provides comprehensive information on the therapeutics under development for Resistant Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Resistant Hypertension. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Resistant Hypertension and features dormant and discontinued products.
GlobalData tracks 13 drugs in development for Resistant Hypertension by 13 companies/universities/institutes. The top development phase for Resistant Hypertension is discovery with four drugs in that stage. The Resistant Hypertension pipeline has 13 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Resistant Hypertension pipeline products market are: Panorama Research Institute, Ionis Pharmaceuticals and AstraZeneca.
The key targets in the Resistant Hypertension pipeline products market include Cytochrome P450 11B2 Mitochondrial, Atrial Natriuretic Peptide Receptor 1, and Calcitonin Gene Related Peptide Type 1 Receptor.
The key mechanisms of action in the Resistant Hypertension pipeline product include Cytochrome P450 11B2 Mitochondrial Inhibitor with four drugs in Phase III. The Resistant Hypertension pipeline products include three routes of administration with the top ROA being Oral and six key molecule types in the Resistant Hypertension pipeline products market including Small Molecule, and Synthetic Peptide.
Resistant Hypertension overview
Resistant hypertension is defined as hypertension that is poorly responsive to treatment and requires the use of multiple medications to achieve acceptable blood pressure ranges. It may be a consequence of secondary hypertension or have no identifiable cause. Resistant hypertension substantially increases the risk of heart attack, stroke and kidney failure
For a complete picture of Resistant Hypertension’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
